Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonoporation-enhanced chemotherapy for inoperable pancreatic cancer
2019-003735-28Phase 2Active
- Sponsor
- Helse Bergen
- Start
- Dec 2020
- Modality
- Small Molecules, Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonazoid, gemcitabine, nab-paclitaxel, fluorouracil, folinic acid and 2 more in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (4 arms), sponsored by Helse Bergen. Primary endpoint: Progression-free survival. Started Dec 2020; status: active.
02
Drugs
sonazoidgemcitabinenab-paclitaxelfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-003735-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003735-28.